JPMorgan analyst Christopher Horvers lowered his price target for Bed Bath & Beyond to $10 from $13 and keeps a Neutral rating on the shares. The company's Q4 sales announcement is evidence that "things are likely to get worse before they get better," Horvers tells investors in a research note. It does not pay to be early to turnarounds, especially in a moderating environment, adds the analyst. Horvers thinks the stock would be in the high-single digit range if it weren't for the potential asset sales ahead, which he believes risks a "sell-the-news event" given the catalyst driven nature of some Bed Bath investors.